Background: Increasing evidence suggests that vascular endothelial growth factor (VEGF) and VEGF receptor (VEGFR) 1 signaling may play an important role in the progression of pathological angiogenesis that occurs in many tumors, including renal cell carcinoma (RCC). Therapeutic targeting directed against VEGF and VEGFR-2 has been proven to be successful for metastatic clear cell RCC (CCRCC). However, the expression of VEGFR-1 and its association with prognostic parameters of CCRCC in the tumorigenesis of renal cancer remains unclear. Therefore, we examined the expression of VEGFR-1 and its prognostic significance in CCRCC.
INTRODUCTION
Renal cell carcinoma (RCC) is the most common renal tumor and accounts for 3% of all malignancies in adults [1] .
The incidence and mortality of renal cancer has increased worldwide, which is probably due to both an increased prevalence of risk factors and an improvement of diagnosis [2] .
According to the cancer statistics in Korea, the incidence of RCC in Korea has shown a steady increase, a trend that has also been seen worldwide [3] . Surgery is an effective treatment for the majority of patients who present with clinically localized RCC. However, metastatic RCC is still difficult to treat and the outcome of patients with metastatic RCC is very poor [4] .
Clear cell RCC (CCRCC), which is the most common subtype of RCC, is mainly associated with mutational inactivation of von Hippel-Lindau (VHL), which plays an important role in tumor growth [5] . The VHL protein negatively regulates hypoxia-inducible factor-1α (HIF-1α) [6] and the activated HIF-1α translocates into the nucleus and induces the transcription of hypoxia-inducible genes,
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including vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), basic fibroblast growth factor (bFGF), and transforming growth factor α (TGF-α) [7] [8] [9] [10] [11] . As a growth factor, VEGF exerts its biological effect mainly through interaction with its two different receptors, VEGF receptor (VEGFR)-1 (Flt-1) and VEGFR-2 (Flk-1), which are selectively expressed on vascular endothelial cells [12] . Therapeutic targeting directed against VEGF and VEGFR-2 has been successful for metastatic RCC treatment [13] . Increasing evidence suggests that VEGF/VEGFR-1 signaling is crucial for angiogenesis of CCRCC, which consists of highly vascularized malignant tumors [14] . Therefore, further characterization of VEGFR-1 expression in CCRCC is needed.
The expression of VEGF and VEGFR-1 has been studied in CCRCC [15, 16] 
Immunohistochemistry (IHC)
Representative tumor site without necrosis and hemorrhage was marked in the paraffin block. The selected tumor area was harvested using a 5-mm Quick-ray tip-punch (Unitma, Seoul, Korea), placed on a 20-pore TMA mold (Unitma), and re-embedded with paraffin. 4-μm sections of TMA blocks were cut and attached onto coated slides.
Immuhistochemical staining was performed using the We used a modified Allred scoring system to evaluate positivity, with staining intensity and distribution being scored separately [19] . The staining intensity was scored as 0 points (negative), 1 point (weak), 2 points (intermediate),
or 3 points (strong) and the distribution of positive-stained cells was assessed as 0 point (negative), 1 point (<1%), 2 points (1-10%), 3 points (11-33%), 4 points (34-67%), or 5 points (>67%). The total staining score was calculated as the sum of two parameters. Total staining scores from 0 to 2 points were considered negative, while scores from 3 to 8 points were considered positive. The mean staining scores were also compared as continuous variables in each group.
Western blot analysis
The six cases of CCRCC with adjacent normal kidney parenchyma were lysed using 2 mL of PRO-PREP lysis buffer (iNtRon Biotechnology, Daejeon, Korea), and then ground for 15-20 sec on ice using a homogenizer (ProScience, Woburn, MA, USA). The lysates were centrifuged at 13,000 rpm for 15 min. The protein concentration was measured using the Bradford protein assay. An amount of 10 ug of protein from each sample was used for sodium dodecyl sul- 
fate-polyacrylamide gel electrophoresis (SDS-PAGE).
Proteins were transferred to immobilon-P membranes 
Statistical analysis
Statistical analysis was performed using PASW, version 20.0 (SPSS Inc., Chicago, IL, USA). χ 2 test, student's t-test, and ANOVA were used to compare the categorical and continuous variables. The period of overall survival was measured from the date of surgery to the date of death due to the tumor. Tumor recurrence was defined as the presence of clinically diagnosed or pathologically confirmed metastases after surgery. Survival rates were analyzed using the Kaplan-Meier method and compared using the log-rank test.
A value of p < 0.05 was considered statistically significant.
RESULTS
General clinicopathological characteristics
Most patients in this study were men with a mean age of 57. Nine patients (7.1%) had tumor recurrence. Twelve patients (9.5%) died due to the tumor at the time of the last follow-up. These data are summarized in Table 1 .
Expression pattern of VEGFR-1 and its correlation with CCRCC prognostic factors
The IHC staining showed that VEGFR-1 was observed in the membrane and/or cytoplasm of the tumor cells (Fig. 1) . In paired fresh tissues, VEGFR-1 was expressed in both CCRCC and normal renal parenchymal tissue ( Fig. 2A) . We found a significant reduction of VEGFR-1 in tumor tissue compared to non-tumor tissue (Fig. 2B ). In addition, the expression level of VEGR-1 was significantly elevated in low grade tumors compared to high grade tumors (Fig. 2C) . Although VEGFR-1 expression seems to be higher in cases without the sarcomatoid feature, tumor necrosis, perirenal fat, renal sinus fat, and vascular invasion, and is lower in cases with cystic change, these differences were not statistically significant. Moreover, 50% of cases with pathologic T stage 1 were VEGFR-1 positive, as were 38.9% of cases with pathologic T stage 2-4 cases, which was not significant. The difference was not statistically significant (Table 3) .
However, there was no significant difference of survival and recurrence rate between VEGFR-1 positive and negative groups (p=0.180 and p=0.372, respectively).
DISCUSSION
There are several well-known prognostic factors, which can be used to predict the prognosis of RCC. The Fuhrman nuclear grading system is an example of an important prognostic factor and is divided into grades 1 to 4 [18] . Another reliable prognostic factor is the TNM staging system, which takes into account tumor size and the extent of the tumor [17] . Other pathologic factors that give poor prognosis include the presence of tumor necrosis, sarcomatoid and rhabdoid features, vascular, perirenal fat, renal pelvis, and renal sinus fat invasions [20] . In contrast, the presence of cystic change in CCRCC is known to be a favorable prognostic factor [21] .
We found that VEGFR-1 expression was identified in the membrane and/or cytoplasm in 46.8% cases of CCRCC.
Higher VEGFR-1 expression was significantly related to a lower Fuhrman nuclear grade and the absence of renal pelvis invasion. In addition, the results of Western blot analyses showed that expression of VEGFR-1 was significantly higher in adjacent normal tissue than in CCRCC tissue.
Moreover, there was a significant difference in VEGFR-1 expression between low and high grade tumors. Therefore, we suggest that high VEGFR-1 expression may be asso- RCC is a malignant tumor that is characterized by high tumor vascularity and VEGF is the most important angiogenic factor. VEGF (also referred to as VEGFA) belongs to a gene family that consists of placental growth factor (PLGF), VEGFB, VEGFC, and VEGFD [22] . The VEGF gene is composed of eight exons and is differentially spliced to encode four major isoforms, including VEGF121, VEGF165, VEGF189, and VEGF206 [23] . The importance of VEGF and VEGFR-1 in regulating tumor angiogenesis in CCRCC has been reported previously [15, 16] . One study suggests that knockdown of VEGFR-1 impairs growth of CCRCC [14] . Ljungberg et al. [16] found that the VEGF, VEGFR-1, and VEGFR-2 mRNA levels were higher in tumors compared to the normal kidney cortex, which is contrary to our results. However, it has been suggested that VEGFR-1 may not be the primary receptor transmitting a mitogenic signal, but rather it is a 'decoy' receptor, able to negatively regulate the activity of VEGF on the vascular endothelium, preventing VEGF from binding to VEGFR-2 [24] . The functions and signaling properties of VEGFR-1 can be different depending on the developmental stage of the animal and the cell type [22] .
HIF-1α induces transcription of several factors such as VEGF/VEGFR [8] . Overexpression of HIF-1α is associated with poor prognosis of cervical and breast cancers [25, 26] .
In contrast, elevated HIF-1α expression is correlated with better survival in patients with CCRCC, although no association with tumor stage was found [27] . Furthermore, higher VEGF mRNA levels are associated with a better prognosis in CCRCC [16] . Similarly, our present study showed that higher VEGFR-1 expression may be correlated with favorable prognostic factors for CCRCC, including the Fuhrman nuclear grading system, which showed significant correlation. Further study is required to understand the underlying mechanism of VEGF/ VEGFR-1 signaling pathways in CCRCC.
In clinical practice, sorafenib, sunitnib, bevacizumab, temsirolimus, everolimus, pazopanib, and axitinib, drugs which block the VEGF and mTOR pathways, are logical therapeutic targets for the treatment of metastatic RCC [13] . The development of these targeted agents has substantially improved the survival of patients with metastatic RCC to over 2 years [4] . Although tumor shrinkage is achieved to some extent in a large proportion of RCC patients, complete remissions are uncommon, and thus these treatments are not curative [13] . Therefore, better molecular markers should be studied and developed for the treatment of metastatic RCC.
In conclusion, this study examined VEGFR-1 expression in CCRCC, and its expression was compared to clinicopathological parameters and survival data. We demonstrated that
higher VEGFR-1 expression may be correlated with favorable prognostic factors of CCRCC and significantly correlated with a lower Fuhrman nuclear grade.
